Get SEC filing alerts via email and in your feed for Merus N.V.
MRUS
Merus N.V.
About Merus N.V.
Merus N.V. is a Dutch oncology company specializing in developing innovative multispecific antibody therapeutics using proprietary platforms like Biclonics®, Triclonics®, and ADClonics®. Its pipeline includes antibody candidates targeting solid tumors, including NRG1 fusion cancers, with FDA-approved therapies and ongoing clinical trials. The company collaborates globally to advance cancer treatments that harness immune mechanisms and target multiple tumor pathways.
This description was generated via AI from an annual report.
Updated 9 months ago.